Inicio
Entrar
Ayuda
Buscar en este sitio:
Ensayos Registrados
Por tipo de intervención
Por estado de reclutamiento
Por promotor
Por fecha de registro
Búsqueda avanzada de ensayos
Proceso de Registro
Para registrar un ensayo
Formulario del Promotor
Formulario de ensayos del RPCEC
Para actualizar un ensayo registrado
Para reportar los resultados de un ensayo registrado
Inicio
|
Post–authorizacion study on safety in sentinel sites in adult patients with chronic kidney disease undergoing dialysis
View current
Revisiones
List all revisions
Ver
Compare to current
28 Octubre 2026 - 9:41am
por CIM
28 Octubre 2026 - 9:44am
por CIM
Cambios a
Type study
-
Interventional
+
Observational
Cambios a
Record Verification Date
-
2026/10/
08
+
2026/10/
28
Cambios a
Next update date
-
2027/10/
08
+
2027/10/
28
Revisión de 28 Octubre 2026 - 9:44am
Post–authorizacion study on safety in sentinel sites in adult patients with chronic kidney disease undergoing dialysis
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Scientific title:
Post –authorizacion study on safety in sentinel sites in adult patients with chronic kidney disease undergoing dialysis.
Secondary indentifying numbers:
ior®EPOCIM (new production) 2K-4K-ERC/2025
Issuing authority of the secondary identifying numbers:
Center of Molecular Immunology (CIM)
Primary sponsor:
Center of Molecular Immunology (CIM)
Secondary sponsor:
Not applicable
Source(s) of monetary or material support:
Center of Molecular Immunology (CIM)
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Only approved by Ethics Committees
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Jorge
Midle name:
Francisco
Last name:
Perez-Oliva Diaz
Medical Specialty :
Second degree specialist in nephrology
Affiliation:
Institute of Nephrology “Dr Abelardo Buch Lopez”
Postal address:
Avenida 26 y Rancho Boyeros, Municipio Plaza de la Revolucion
City:
Havana
País:
Cuba
Zip Code:
10600
Telephone:
+53-53888120
Email address:
perezolivajorge955@gmail.com
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Havana, Hermanos Ameijeiras Clinical-Surgical Hospital, Dagoberto Semanat Vaillant, MD., First degree specialist in nephrology
Havana, Dr. Salvador Allende Clinical-Surgical Teaching Hospital, Amarilis Platero Diaz, MD.,First degree specialist in nephrology
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Pending
Date of first enrollment:
19/10/2026
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
Chronic Kidney Disease
Health condition(s) code:
Renal Insufficiency, Chronic
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Urogenital Diseases
Health condition keyword:
-
Intervention(s):
Ior®EPOCIM group (Experimental): ior®EPOCIM (in bulbs 2000 UI, 4000 UI o 10 000 UI) in regular doses of 30 to 100 UI/kg/weekly, intravenously (IV) or subcutaneously (SC) for a year.
Intervention code:
Erythropoietin
Injections, Intravenous
Injections, Subcutaneous
Intervention keyword:
ior® EPOCIM
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
Serious adverse reactions (Exposure dose and dose range, specifically for adverse events of interest, such as: severe hypertension, acute myocardial infarction, stroke, thromboembolism, and death). Measurement time: up to one year of treatment.
Key secondary outcomes:
1-Hemoglobin level at the time of severe RAM-Adverse drug reaction (Expressed in g/dl). Measurement time: at the time of the adverse drug reaction during the year of treatment. 2-Hematocrit level at the time of severe RAM (Expressed in %). Measurement time: at the time of the adverse drug reaction during the year of treatment. 3-Transfusions (number of transfusions received). Measurement time: Monthly, during the year of treatment.
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male/Female
Minimum age:
18 years
Maximum age:
None
Inclusion criteria:
1.Diagnosis of Chronic Kidney Disease in dialysis program (hemodialysis or peritoneal dialysis). 2. Adult patients (> 18 years). 3. Initiation of treatment with new production erythropoietin or change from another erythropoietin to this within the last 30 days. 4. Signed informed consent.
Exclusion criteria:
1. Cancer patients. 2. Patients with uncontrolled hypertension. 3. Patients with hypersensitivity to human albumin.
Type of population:
Adults
Type of participant:
Patients
Study design
Section to complete information about the characteristics of the study design.
Type study:
Observational
Purpose:
Treatment
Allocation:
N/A: single arm study
Masking:
Open
Control group:
Uncontrolled
Study design:
Single group
Phase:
N/A
Target sample size:
NA
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Giselle
Last Name:
Saurez Martinez
Specialty:
Specialist in Comprehensive General Medicine and Pharmacology
Affiliation:
Center of Molecular Immunology (CIM)
Postal Address:
Calle216 esq. 15. Atabey. Playa
City:
Havana
País:
Cuba
Zip Code:
11600
Telephone:
+53-72717933 ext. 3653. mobile: +53-58179946
Email :
giselle@cim.sld.cu
saurezgiselle@gmail.com
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Jorge
Middle Name:
Francisco
Last Name:
Perez-Oliva Diaz
Specialty:
Second degree specialist in nephrology
Affiliation:
Institute of Nephrology “Dr Abelardo Buch Lopez”
Postal Address:
Avenida 26 y Rancho Boyeros, Municipio Plaza de la Revolucion
City:
Havana
País:
Cuba
Zip Code:
10600
Telephone:
+53-53888120
Email :
perezolivajorge955@gmail.com
Data Sharing
Section to complete the data related to the data sharing plan.
Data sharing plan:
No
Research Ethics Committees
Section to complete the data related to the review ethics committees.
Name of Research Ethics Committees:
Institute of Nephrology “Dr Abelardo Buch Lopez”
Hermanos Ameijeiras Clinical-Surgical Hospital
Dr. Salvador Allende Clinical-Surgical Teaching Hospital
Status of evaluation:
Approved
Approved
Approved
Status of evaluation date of Ethic Committee:
11/02/2026
01/09/2026
13/05/2026
Postal address of Ethic Committee :
Avenida 26 y Rancho Boyeros, Municipio Plaza de la Revolucion. ZC: 10600, Havana, Cuba.
San Lazaro # 701 esq. a Belascoain, Centro Habana. ZC:10400, Havana, Cuba
Calle Calzada del cerro #1551 esq. Domínguez, Cerro. ZC: 12000, Havana, Cuba.
Telephone:
+53-52427217
+53-53834650
+53-53256989
Correo electrónico:
alvarezyanet@infomed.sld.cu
bertglezm@infomed.sld.cu
raisa.baguer@infomed.sld.cu
About study completion
Section to complete the data related to the study completion.
Study completion date:
27/10/2028
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000486
Date of Registration in Primary Registry:
08/10/2026
Record Verification Date:
2026/10/28
Next update date:
2027/10/28
Link to the spanish version:
Click here
Acerca del RPCEC
Estructura y Gobernanza
Política
Publicaciones
Reconocimientos
Comunicaciones
Noticias
Recursos útiles
Fundamentos del registro
Bibliografías en ensayos clínicos
Regulaciones cubanas
Otros registros
Plataforma Internacional de Registros de Ensayos Clínicos